APP and myeloid sarcoma: B: Benefits; R: Risks; MS: Multiple sclerosis; EAE: Experimental autoimmune encephalomyelitis; CNS: Central nervous system; APP/PS1: Amyloid precursor protein/presenilin 1; GLP-1 RA: Glucagon-like peptide –1 receptor agonist; AEs: adverse events; FAERS: Food and Drug Administration Adverse Event Reporting System; ROR: reporting odds ratio; CI: confidence interval